The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism.
Reyes-Farias M, Carrasco-Pozo C. · 2019
Read The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. by Reyes-Farias M, Carrasco-Pozo C. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6651418.txt.
Introduction
Reyes-Farias and Carrasco-Pozo review the anti-cancer effects of quercetin on tumour metabolism. Their review appears in the International Journal of Molecular Sciences. Quercetin is a common dietary flavonoid in fruits and vegetables. Cancer cells reprogram their metabolism to grow fast. They favour glycolysis for building blocks over efficient energy output. That rewiring is a hallmark of malignancy. Quercetin presses on several of the control pathways. These include PI3K/Akt/mTOR and Wnt/beta-catenin signalling.
Through them it cuts cell viability and drives apoptosis. It also promotes autophagy in cancer cells. The review focuses on glucose handling and mitochondria. Those two fronts define the metabolic attack. The authors present quercetin as a low-cost adjunct candidate.
Catalog record
| CREATOR | Reyes-Farias M, Carrasco-Pozo C. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism By Marjorie Reyes-Farias, Catalina Carrasco-Pozo Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms20133177 ABSTRACT Abstract Cancer is a problem with worldwide importance and is the second leading cause of death globally. Cancer cells reprogram their metabolism to support their uncontrolled expansion by increasing biomass (anabolic metabolism—glycolysis) at the expense of their energy (bioenergetics-mitochondrial function) requirements. In this aspect, metabolic reprogramming stands out as a key biological process in understanding the conversion of a normal cell into a neoplastic precursor. Quercetin is the major representative of the flavonoid subclass of flavonols. Quercetin is ubiquitously present in fruits and vegetables, being one of the most common dietary flavonols in the western diet. The anti-cancer effects of quercetin include its ability to promote the loss of cell viability, apoptosis and autophagy through the modulation of PI3K/Akt/mTOR, Wnt/β-catenin, and MAPK/ERK1/2 pathways. In this review, we discuss the role of quercetin in cancer metabolism, addressing specifically its ability to target molecular pathways involved in glucose metabolism and mitochondrial function. Keywords: quercetin, cancer, glycolysis, mitochondrial function, PI3K/Akt pathway Cancer is a problem with worldwide importance and is the second leading cause of death globally. In 2018, there were 18.1 million new cases of cancer and 9.6 million deaths caused by cancer disease [1]. This pathology causes a high economic impact on public and private health. For example, in the US, the total annual economic cost due to cancer was US$ 1.16 trillon in 2010 [2]. Cancer Tomorrow has predicted that in 2040 there will be a 63.1% increase in new cases of all types of cancer (29.5 million more) compared to 2018 [3]. The types of cancer with the highest incidence worldwide are lung (11.6% of total), breast (11.6%), colorectal (10.2%), prostate (7.1%), and stomach cancer (5.7%). The highest rates of world deaths are associated with lung (18.4%), colorectal (9.2%), stomach (8.2%), liver (8.2%), and breast cancer (6.6%). Regarding incidence, mortality, and 5 year prevalence by region, Asia has the highest levels (48.4%, 57.3%, and 39.7%, respectively), followed by Europe (23.4%, 20.3%, and 27.7%, respectively) and North America (13.2%, 7.3%, and 18.5%, respectively) [2]. Although high incidence rates are associated with high-income countries [4], 70% of deaths from cancer occur in low- and middle-income countries [5]. Considering these elevated statistics, it is relevant to work on therapeutic strategies to prevent and treat cancer. In this sense, it has been reported that dietary natural products could be a cost-effective alternative, as they can be regularly delivered by the diet, to promote cancer prevention or complement pharmacological therapies in cancer treatment. 1. AEROBIC GLYCOLYSIS AS ENERGETIC SOURCE IN CANCER CELLS Deregulation of cell proliferation is a prerequisite for carcinogenesis. A single genetically altered cell causes abnormal proliferation, which leads to the outgrowth of a population of clonally derived tumor cells. However, for this to be possible, the production of biomass and energy are key points to allow and sustain uncontrolled cell expansion [6]. As a tumor is characterized by limited nutrient availability, cancer cells undergo competitions for nutrients with other types of cells, which are part of their microenvironments [7,8]. Therefore, uncontrollable cell proliferation and tumor formation induce a change in metabolic requirements, as well as in nutrient and oxygen cellular availability [9,10], which promotes metabolic reprogramming [11,12,13]. Because the tumor environment is limited in nutrients, it is important that these cells have a mechanism to support energy demand for proliferation and cell growth. Likewise, it has been described that a change in glucose metabolism called the “Warbug Effect” occurs in cancer cells [14,15]. Basically, in cancer, cells favour metabolism via aerobic glycolysis with the accumulation of lactate, in contrast to the more energetic, efficient oxidative phosphorylation that occurs in normal cells [6]. This switch in cell metabolism is beneficial for cancer progression and resistance to therapy [6,16,17]. Aerobic glycolysis is an inefficient way to produce ATP because it only generates 2 ATPs per molecule of glucose, compared with oxidative phosphorylation, which generates 36 ATPs per molecule [18]. However, aerobic glycolysis remains the preferred metabolic mechanism for cancer cells because biomass production is prioritized over energy production [7,19]. In this sense, in cancer cells, glycolysis generates high levels of carbon-rich metabolic intermediates that could be utilized as precursors for de novo synthesis of nucleotides, lipids, or amino acids [20,21]. Specifically, glucose-6-phosphate and fructose-6-phosphate, glyceraldehyde-3-phosphate, and 3-phosphoglycerate are glycolytic intermediates that are substrates for nucleotide, aminoacid and lipid biosynthesis [21]. 2. MOLECULAR NETWORK THAT UNDERLIES METABOLIC REPROGRAMMING IN CANCER In cancer cells, metabolic reprogramming is regulated by several pathways, including the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), which promotes an increased glucose uptake and glycolysis [22,23]. PI3K transduces the signal across messengers that activate Akt, and thus completely active, the PI3K/Akt pathway regulates cell angiogenesis, metabolism, growth, proliferation, survival, protein synthesis, transcription and apoptosis [24,25]. Akt is involved in pathways that control the availability of nutrients by acting through AMP-activated protein kinase (AMPK). AMPK controls glucose and lipid metabolism by sensing changes in nutrient and extracellular energy levels [26]. AMPK is an energy sensor that is activated when intracellular levels of AMP are high. Stresses that stimulate ATP consumption or inhibit ATP production result in an increased AMP:ATP ratio, promoting AMPK activation [27]. Interestingly, AMPK can exert pro- or anti-tumor effects based on the metabolic context. AMPK activation promotes net ATP conservation by activating pathways of catabolic metabolism and inhibiting anabolic processes that consume ATP [27]. Under metabolic stress, AMPK can support tumorigenesis by promoting metabolic plasticity through stimulating alternative metabolic pathways, including mitophagy and fatty acid oxidation. However, AMPK activation can also inhibit cell growth by inducing a p53-mediated cell cycle arrest, thereby downregulating mammalian target of rapamycin C1 (mTORC1) activity [27]. Akt activation increases glycolysis by promoting hexokinase 2, which directly interact with the mitochondrial pore to prevent the release of apoptotic proteins [28]. In addition, Akt activates mTORC1/2 [29], which regulates the downstream signaling of protein and lipid synthesis, metabolism, cell survival and apoptosis [29,30,31]. The activated mTOR directly or indirectly stimulates metabolic reprogramming by activating key transcription factors, such as c-Myc, cyclin D, and hypoxia-inducible transcription factor 1 alpha (HIF-1α), even under normoxic conditions [32]. Major oncogenes, such as c-Myc, and HIF-1α, are reported to be master inducers of cancer glycolysis through direct or indirect transactivation of cancer glycolytic genes [33]. In normal cells, c-Myc expression is induced upon growth factor stimulation and involved in many biological processes, including proliferation, cell cycle progression, cell growth, metabolism, angiogenesis, differentiation, cell adhesion, and mobility [34]. However, in cancer cells, c-Myc expression promotes energy production and anabolic processes, which are required for rapid proliferation, independent of growth factor stimulation. c-Myc influences glucose metabolism by up-regulating the gene expression of glucose transporters and many glycolytic enzymes, such as pyruvate kinase, as well as lactate dehydrogenase A (LDH-A) [34]. HIF-1α is involved in adaptive responses upon reduced oxygen availability and is a transcription factor that controls glycolytic gene expression. In fact, HIF-1α is the primary driver of increased glycolysis and lactate production during hypoxia [35]. In addition, HIF-1α up-regulates the vascular endothelial growth factor (VEGF), erythropoietin (EPO), glucose transporter 1 (GLUT1), and glycolytic enzymes genes under normal O2 conditions [36,37].